
Cagrilintide
Cagrilintide has randomized human trials, both alone and combined with semaglutide, showing meaningful weight loss in people with overweight or...
About:
A long-acting amylin analogue studied in obesity trials, including in combination with semaglutide.
What does this peptide do?
Backed by human trial data, narrower than the strongest evidence. Research focuses on obesity.

Obesity research
An amylin analogue studied in obesity trials, including with semaglutide.
Evidence grade
BHighest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.
What are the benefits and side effects of this peptide
What research says it may help with
- Cagrilintide has randomized human trials, both alone and combined with semaglutide, showing meaningful weight loss in people with overweight or obesity.
Who should avoid it
- People who are pregnant or breastfeeding
- Children and adolescents
- Known hypersensitivity to the compound
- Personal or family history of medullary thyroid carcinoma when combined with GLP-1 agents
See the safety section. Absence of a flag is not evidence of safety.
A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.

How to store this peptide
Supplied as a prefilled pen or vial in the licensed product. Store refrigerated before first use and follow the product leaflet.
Lyophilized storage
Store at −20 °C, protected from light.
Reconstituted storage
Keep at 2–8 °C and use within a short period. For longer storage, aliquot and freeze at −20 °C.
Storage Handling
Avoid repeated freeze–thaw cycles. Let the vial reach room temperature before opening.
Related research
Related research is coming soon for this peptide.


